PGEN Surges 12% on Q1 2026 Revenue Beat Driven by Papzimeos Launch
Precigen's Q1 2026 revenue rose to $23.3M, surpassing expectations as its new cancer therapy gains traction. Precigen (PGEN) shares jumped nearly 12% Thursday after reporting Q1 2026 revenue of $23.3M, a $21.9M increase from the prior-year period. The gain was fueled by st